Drug common name | Lxh254 |
INN | naporafenib |
Description | Lxh254 is a small molecule pharmaceutical. It is currently being investigated in clinical studies. It is known to target platelet-derived growth factor receptor beta, RAF proto-oncogene serine/threonine-protein kinase, epithelial discoidin domain-containing receptor 1, serine/threonine-protein kinase B-raf, and discoidin domain-containing receptor 2. |
Classification | Small molecule |
Drug class | — |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | Cc1ccc(NC(=O)c2ccnc(C(F)(F)F)c2)cc1-c1cc(OCCO)nc(N2CCOCC2)c1 |
PDB | — |
CAS-ID | 1800398-38-2 |
RxCUI | — |
ChEMBL ID | CHEMBL4583691 |
ChEBI ID | — |
PubChem CID | — |
DrugBank | — |
UNII ID | 15JL80DG6H (ChemIDplus, GSRS) |